Investors
Our commitment to scientific excellence, operational efficiency, and customer focus positions us as a preferred partner in the industry. In this section, we highlight how Sai Life Sciences drives growth through strategic investments in infrastructure, technology and talent, all aimed at delivering value to our stakeholders.
Annual Reports
Corporate Governance policies
- Anti-Sexual Harassment Policy
- Archival Policy
- Code of Conduct for BoD and SMPs
- Code of Practices-Fair Disclosure of UPSI
- Corporate Social Responsibility Policy
- Determining Material Subsidiaries
- Dividend Distribution Policy
- Insider Trading Policy
- Nomination and Remuneration Policy
- Policy for Determination of Materiality
- Policy for Evaluation of Performance of BoD
- Policy for Familiarisation Programme for ID
- Policy for Preservation of Documents
- Policy on Related Party Transactions
- Policy to Promote Diversity of Board of Directors
- Risk Management Policy
- Succession Policy
- UPSI Leak Inquiry Policy
- Whistle Blower Policy
Material Documents
- Certified copies of MoA and AoA
- Certificate of Incorporation
- Certificate of commencement for business
- BR approving the Offer and related matters
- SR approving Fresh Issue and other related matters
- BR approving DRHP
- BR approving RHP
- BR taking on record the approval for OFS by each of selling shareholders
- IPO committee resolution taking on record consent to participate in OFS by each of selling shareholders
- Audit committee resolution approving KPIs for disclosure
- BR and SR for approval of revised remuneration structure of MD and CEO
- BR and SR for approval of revised remuneration structure of Chairman and WTD
- Scheme of arrangement between Company, Sai Quest Syn and their respective shareholders and creditors along-with Valuation report
- Gift Deed along-with supplementary letter
- Consent letters and authorisations from selling shareholders
- Deloitte Consent Letter
- Vishvakarma Consultancy Services Consent Letter
- Annual Reports of the Company for Fiscal year 2024
- Annual Reports of the Company for Fiscal year 2023
- Annual Reports of the Company for Fiscal year 2022
- Examination Report
- Loan utilization certificate
- Statement of Possible Special Tax Benefits certificate
- Consents by Directors, Company Secretary, Compliance Officer and Legal Head, legal counsels to the Company, Bankers to the Company, Banker(s) to the Offer, the BRLMs, Syndicate Members, Registrar to the offer to act in respective capacities
- Certificate by Bashetty & Joshi certifying KPIs
- Certificate by Bashetty & Joshi certifying Basis for Offer price
- Certificate by Bashetty & Joshi certifying weighted average cost of acquisition
- Certificate by Bashetty & Joshi certifying details of Employee Stock options scheme
- Certificate by Bashetty & Joshi certifying details of outstanding borrowings
- Certificate by Bashetty & Joshi certifying dues owed to material creditors, MSME enterprises and other creditors
- Frost & Sullivan report
- Frost & Sullivan consent
- Shareholders’ agreement dated March 27, 2019 along-with amendment agreement dated July 4, 2024
- Agreement dated November 27, 2023 along-with amendment agreement dated July 10, 2024
- Due diligence certificate dated July 24, 2024
- In-principle listing approvals by NSE and BSE
- SEBI Final observation letter
- Tripartite agreement between Company, NSDL and Registrar of the Offer
- Tripartite agreement between Company, CDSL and Registrar of the Offer